Patents by Inventor Hector ALDAZ

Hector ALDAZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11976136
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 7, 2024
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Publication number: 20210054103
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Application
    Filed: July 17, 2020
    Publication date: February 25, 2021
    Inventors: Hector ALDAZ, Shane Krummen ATWELL, Stephen John DEMAREST, Karen Jean FRONING, Brian Arthur KUHLMAN, Andrew Philip LEAVER-FAY
  • Patent number: 10774156
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 15, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Publication number: 20180009908
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Applicants: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Patent number: 9328173
    Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 3, 2016
    Assignee: Eli Lilly and Company
    Inventors: Hector Aldaz, Barrett Allan, Ling Liu, Jirong Lu, Ying Tang, Sheng-Hung Rainbow Tschang, Pia Pauliina Yachi
  • Publication number: 20150175708
    Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 25, 2015
    Inventors: Hector ALDAZ, Barrett ALLAN, Ling LIU, Jirong LU, Ying TANG, Sheng-Hung Rainbow TSCHANG, Pia Pauliina YACHI